Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma

NCT06119217 is registered in ClinicalTrials.gov with Trishula Therapeutics, Inc. as lead sponsor.

NCT NCT06119217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06119217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients Not Previously Treated for Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Trishula Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 25, 2024
Completion date
March 6, 2026
Enrollment
194 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer